New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:55 EDTVTLVital Therapies price target raised to $35 from $20 at Canaccord
Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
News For VTL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2015
16:23 EDTVTLOn The Fly: Top stock stories for Monday
Subscribe for More Information
12:17 EDTVTLOn The Fly: Top stock stories at midday
Subscribe for More Information
09:45 EDTVTLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:18 EDTVTLOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTVTLVital Therapies downgraded to Underperform from Buy at BofA/Merrill
Subscribe for More Information
07:47 EDTVTLVital Therapies price target lowered to $8 from $35 at Canaccord
Subscribe for More Information
07:33 EDTVTLVital Therapies downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
07:32 EDTVTLVital Therapies downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
06:54 EDTVTLVital Therapies downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Vital Therapies to Neutral following the announcement VTI 208 missed its primary endpoint but sees the potential for approval in a lower MELD score cohort in the 2020 time frame. The firm lowered its price target on shares to $9 from $25.
August 21, 2015
16:33 EDTVTLVital Therapies down 77% after results of VTI-208 fail to achieve endpoints
Subscribe for More Information
16:12 EDTVTLVital Therapies to resume trading at 4:30 pm ET
Subscribe for More Information
16:03 EDTVTLVital Therapies says topline results of VTI-208 fail to achieve endpoints
Subscribe for More Information
August 19, 2015
07:00 EDTVTLVital Therapies volatility elevated into topline clinical trial results
Vital Therapies August call option implied volatility is at 188, September is at 234; compared to its 52-week range of 70 to 423, suggesting large price movement into expected release of topline results of the VTI-208 clinical trial.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use